Yolk-shell shaped Au-Bi2S3 heterostructure nanoparticles for controlled drug release and combined tumor therapy. (5th November 2022)

• Record Type: Journal Article
• Authors: Zhao, Tingting; Zhang, Qin; Cang, Feng; Wu, Shilong; Jiang, Yu; Zhao, Qiyao; Zhou, Yifan; Qu, Xiaomeng; Zhang, Xuesong; Jin, Yushen; Li, Yanyan; Fu, Yujie
• Is Part Of: Nanotechnology. Volume 33:Number 45(2022)
• Publication Date: 2022-11-05
• Subjects: bismuth sulfide nanomaterials -- drug delivery -- synergistic therapy -- phase change materials; Nanotechnology -- Periodicals; Nanotechnology -- Periodicals; Nanotechnology; Publications périodiques; Nanotechnologies; Periodicals; 620.5
• DOI: 10.1088/1361-6528/ac85c2
• Languages: English
• ISSNs: 0957-4484

Abstract

Abstract: To fabricate a novel stimuli-responsive system enabling controlled drug release and synergistic therapy, yolk-shell shaped bismuth sulfide modified with Au nanoparticles (Au-Bi2 S3 ) was prepared. The Au-Bi2 S3 nanomaterial with heterojunction structure exhibited excellent photothermal conversion efficiency and considerable free radicals yield under laser irradiation. The drug delivery capacity was confirmed by co-loading Berberine hydrochloride (BBR) and a phase change material 1-tetradecanol (PCM), which could be responsible for NIR light induced thermal controlled drug release. In vitro investigation demonstrated that Au-Bi2 S3 has cell selectivity, and with the assistance of the properties of Au-Bi2 S3, the loaded drug could give full play to their cancer cell inhibition ability. Our work highlights the great potential of this nanoplatform which could deliver and control Berberine hydrochloride release as well as realize the synergistic anti-tumor strategy of photothermal therapy, photodynamic therapy and chemotherapy for tumor therapy.